Ornithine Aspartate Liposome (CAT#: LDLY-1023-LD4)

Ornithine aspartate liposomes are primarily used in research focused on liver diseases, especially hepatic encephalopathy. They help in detoxifying ammonia by enhancing the urea cycle, thus improving liver function and reducing symptoms related to liver disease.

Encapsulating ornithine aspartate in liposomes enhances its bioavailability and targeting efficiency. This targeted delivery system ensures that higher concentrations of the active ingredients reach the liver, maximizing therapeutic effects while minimizing potential systemic side effects.

The liposomal delivery system can provide a controlled release of ornithine aspartate, which helps maintain optimal therapeutic levels over extended periods. This method potentially reduces the frequency of dosing and improves patient compliance, particularly important in managing chronic conditions.

Ornithine aspartate liposomes typically contain a combination of the amino acid ornithine and aspartic acid, encapsulated within standard liposomal structures such as phospholipid bilayers. This encapsulation helps in targeting liver cells and facilitates the more efficient use of the amino acids in ammonia detoxification.

These liposomes are prepared under sterile conditions to ensure purity and stability. They should be stored in a refrigerator to maintain their structural integrity and functional efficacy until they are ready to be used in clinical or experimental settings.